Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”